B3bio Inc., a biotechnology company founded in 2007 with an expertise in RNA therapeutics, has joined The Hamner Institutes for Health Sciences in Research Triangle Park.
Pioneer AIDS researcher and co-founder of Trimeris, Dani P. Bolognesi, Ph.D, joined with Bruce Sullenger, Ph.D, Andrew Ellington, Ph.D., and Robert R. Bonczek to create b3bio.
The goal of the company's technology, licensed from Duke University and the University of Texas, is to develop an entirely new class of medicines using small RNA molecules to target individual cells and tissues with remarkable precision. If successful, it could be used to treat cancer, inflammation and infection, as well as improve upon current treatments by reducing unwanted side effects.
B3bio, Inc. is part of The Hamner Accelerator for Translational Bioscience, a program that enables emerging companies and academic institutions to access resources, research project partnerships and grant funding. To support companies like b3bio, Inc., The Hamner collaborates with the NC Biotechnology Center, the Council for Entrepreneurial Development, university business schools and other entrepreneurial programs to facilitate commercialization of new technologies.